Pulmonary inflammation is the immune system’s response to injury or threat inside the lungs, and it sits at the core of conditions ranging from pneumonia and asthma to acute respiratory distress syndrome (ARDS). When triggered by infection, inhaled particles, or a misfiring immune response, immune cells flood the lung tissue and release signaling molecules that cause swelling, fluid buildup, and tissue damage. The process can be brief and self-limiting or chronic and progressive, and understanding what drives it shapes every decision about diagnosis and treatment.
What Happens Inside Inflamed Lungs
The lungs depend on an extremely thin barrier between the air sacs (alveoli) and the surrounding blood vessels. When that barrier is compromised, fluid leaks into spaces that should contain only air, and oxygen transfer into the bloodstream drops. In acute lung injury and ARDS, this increased permeability of the barrier is the defining problem: fluid accumulates, the tissue swells, and breathing becomes progressively harder.1PubMed Central. Contribution of neutrophils to acute lung injury The resulting mismatch between ventilation and blood flow through the lungs is what produces low oxygen levels in the blood and, in severe cases, the need for mechanical breathing support.2PubMed Central. Pathophysiology and Clinical Meaning of Ventilation-Perfusion Mismatch in the Acute Respiratory Distress Syndrome
Neutrophils, a type of white blood cell, are among the first responders. They rush into the lung tissue and the air spaces, attacking whatever triggered the alarm. But they also release enzymes and toxic molecules that damage healthy tissue in the process. Research in mouse models has shown that depleting neutrophils during lung injury can reduce damage to the proteins holding the barrier together and delay the progression of disease.3PubMed. Early disruption of the alveolar-capillary barrier in a ricin-induced ARDS mouse model: neutrophil-dependent and -independent impairment of junction proteins The immune system’s own weaponry, in other words, is a major source of collateral damage.
Alongside neutrophils, the lungs release inflammatory signaling molecules. Three of the most studied are TNF-α, IL-1β, and IL-6. TNF-α acts as an early alarm during infection. IL-1β amplifies the inflammatory cascade and, at high levels, can contribute to organ failure. IL-6 serves as a marker of the intensity of the inflammatory response.1PubMed Central. Contribution of neutrophils to acute lung injury These molecules do not work in isolation; they recruit more immune cells, activate further signaling pathways, and, when uncontrolled, drive the kind of tissue destruction that turns a manageable infection into a life-threatening crisis.
Infectious Causes
Bacterial and viral infections are the most familiar triggers. Bacteria can activate immune sensors on lung cells called toll-like receptors, which set off signaling cascades that ramp up inflammation. What makes respiratory infections particularly dangerous is the phenomenon of co-infection: when a virus and a bacterium hit the lungs at the same time, the inflammatory response is often worse than either pathogen alone would produce. Research using human lung tissue found that dual activation of two different toll-like receptors during co-infection led to an amplified inflammatory response, suggesting that combined infections may be a driver of the severe flare-ups seen in chronic lung diseases.4European Respiratory Journal. Toll-like receptor (TLR)-signaling mediates enhanced inflammatory effects in coinfections of viral and bacterial respiratory pathogens in human lung tissue
Interestingly, the signaling pathways triggered by bacteria can also prime the lungs to respond more aggressively to viruses. Experiments in mouse lung immune cells showed that bacterial components activated one toll-like receptor, which then increased the expression of a different receptor typically associated with viral detection.5Scientific Reports. TLR4 signaling induces TLR3 up-regulation in alveolar macrophages during acute lung injury This crosstalk between pathways means that a prior bacterial exposure may heighten the inflammatory response to a subsequent viral infection, or vice versa. It helps explain why people with chronic lung conditions often experience disproportionately severe flare-ups from seemingly mild new infections.
Environmental Triggers
You do not need an infection for the lungs to become inflamed. Inhaled pollutants, especially fine particulate matter smaller than 2.5 micrometers (PM2.5), can trigger a robust inflammatory response on their own. Lung macrophages, the resident immune cells tasked with clearing inhaled debris, play a central role. When they encounter airborne particles, they produce inflammatory mediators that recruit additional immune cells and sustain the inflammatory process.6PubMed Central. Contribution of lung macrophages to the inflammatory responses induced by exposure to air pollutants
PM2.5 exposure pushes macrophages toward a pro-inflammatory state, increasing their output of TNF-α, IL-6, and IL-1β, the same molecules involved in infection-driven inflammation.7PubMed. Direct effects of airborne PM2.5 exposure on macrophage polarizations The mechanism involves the same toll-like receptor pathways that infections use, followed by activation of a signaling chain that ultimately turns on inflammatory genes.8PubMed. PM2.5 Exposure Induces Inflammatory Response in Macrophages via the TLR4/COX-2/NF-κB Pathway The practical implication is that chronic exposure to polluted air can produce a slow-burning inflammatory state in the lungs even in people who have no infections or allergies, contributing over time to conditions like COPD and asthma exacerbations.
Occupational exposures add another layer. Workers in agriculture, construction, mining, and manufacturing can inhale organic dusts, chemical fumes, and mineral fibers that provoke ongoing immune activation. Cigarette smoke is, of course, the most studied environmental lung toxin. When people quit smoking, the total number of immune cells recovered from the lungs drops within the first month, but macrophages loaded with inflammatory residue persist in the air spaces for well over a year after the last cigarette.9PubMed. Smoking cessation rapidly reduces cell recovery in bronchoalveolar lavage fluid, while alveolar macrophage fluorescence remains high That residual inflammatory material is redistributed from older macrophages to newly recruited ones, extending the inflammatory footprint long after the exposure has stopped.
Autoimmune and Hypersensitivity Reactions
Sometimes the lungs become inflamed because the immune system overreacts to substances that are not inherently harmful. Hypersensitivity pneumonitis is a classic example: repeated inhalation of certain organic dusts, mold spores, or animal proteins triggers an immune-mediated inflammatory response that can cause granuloma formation and, if it persists, scarring of the lung tissue.10PubMed. Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment The reaction is driven primarily by T cells rather than the neutrophils that dominate in acute infections, and it tends to develop over weeks to months of repeated exposure rather than in the span of hours.
Autoimmune conditions such as rheumatoid arthritis, lupus, and inflammatory myopathies can also attack the lungs directly. In these diseases, the same immune dysregulation that targets joints or skin simultaneously inflames the lung tissue, producing what clinicians call interstitial lung disease. The inflammation follows patterns that mirror the underlying autoimmune process: some patients show a predominance of lymphocytes in their lung fluid, others show a neutrophil-heavy pattern, and these differences help guide treatment decisions.11PubMed Central. Correlation of high-resolution computed tomography and immunological bronchoalveolar lavage in interstitial lung disease at the onset of inflammatory rheumatic diseases
Recognizing the Symptoms
The symptoms of pulmonary inflammation depend heavily on the speed and severity of the process. Acute inflammation, as in pneumonia or ARDS, tends to produce sudden shortness of breath, rapid breathing, a persistent cough, chest tightness, and fever. When the barrier between air sacs and blood vessels breaks down quickly, oxygen levels can plummet in hours, leading to confusion, bluish discoloration of the lips and fingertips, and eventually respiratory failure.
Chronic inflammation has a subtler presentation. People with conditions like COPD, chronic hypersensitivity pneumonitis, or autoimmune interstitial lung disease often notice a gradual decline in exercise tolerance, a dry cough that lingers for months, and fatigue that does not improve with rest. Because these symptoms overlap with so many other conditions, chronic pulmonary inflammation is frequently misattributed to deconditioning, anxiety, or aging. The key warning signs that should prompt medical evaluation include breathlessness that is new or worsening, a cough lasting more than a few weeks, unexplained weight loss, and crackling sounds heard during breathing.
How Pulmonary Inflammation Is Diagnosed
Chest imaging is the starting point. High-resolution computed tomography (HRCT) can reveal characteristic patterns that suggest different types of lung inflammation: ground-glass opacities often point toward an active inflammatory process, while a honeycomb pattern suggests established fibrosis. When HRCT findings are ambiguous, bronchoalveolar lavage (BAL), a procedure that washes a small segment of the lung with saline and collects the fluid for analysis, can identify which immune cells are predominant. A lymphocyte-heavy lavage fluid, for instance, was the pattern most commonly associated with ground-glass opacities on HRCT in a study of patients with inflammatory rheumatic diseases.11PubMed Central. Correlation of high-resolution computed tomography and immunological bronchoalveolar lavage in interstitial lung disease at the onset of inflammatory rheumatic diseases
Combining BAL analysis with HRCT tends to outperform either test alone. In the context of invasive pulmonary fungal infections, one study found that using both together achieved about 85% sensitivity and 94% specificity, significantly better than either modality by itself.12Journal of Radiation Research and Applied Sciences. Diagnostic value of bronchoalveolar lavage fluid testing combined with high-resolution computed tomography of patients with invasive pulmonary fungal disease Blood tests for inflammatory markers (C-reactive protein, erythrocyte sedimentation rate, and specific autoantibodies) round out the picture and help distinguish infectious from autoimmune causes.
Corticosteroids as a First-Line Treatment
Corticosteroids remain the workhorse treatment for most forms of pulmonary inflammation. They work by entering cells, binding to receptors in the cytoplasm, and then traveling to the nucleus where they essentially switch off the genes responsible for producing inflammatory molecules. The key mechanism involves recruiting an enzyme that reverses the chemical changes needed for inflammatory genes to be read, effectively silencing them.13PubMed Central. Inhaled Corticosteroids This broad suppression of inflammatory gene activity is what makes corticosteroids effective across such a wide range of lung diseases, from asthma to ARDS to autoimmune interstitial lung disease.
Inhaled corticosteroids deliver the drug directly to the airways, reducing systemic side effects while keeping inflammation in check. They are the backbone of asthma management and play a role in COPD when frequent flare-ups occur. Systemic corticosteroids, taken as pills or given intravenously, are reserved for more severe or widespread inflammation. The trade-offs are well known: long-term use can lead to bone thinning, elevated blood sugar, weight gain, and increased infection risk.
Not everyone responds equally. In some patients with severe COPD or smoking-related inflammation, the enzyme that corticosteroids depend on to silence inflammatory genes becomes less active, making the drugs less effective.14PubMed. Mechanisms and resistance in glucocorticoid control of inflammation This steroid resistance is one of the main reasons clinicians have moved toward more targeted therapies for patients who do not improve on corticosteroids alone.
Biologic Therapies for Targeted Control
When corticosteroids are not enough, biologic drugs offer a more precise approach. These are engineered antibodies that block specific molecules in the inflammatory cascade rather than suppressing the immune system broadly. Current options for severe asthma, for example, include drugs targeting IgE, IL-5, the IL-5 receptor, IL-4/IL-13, and a molecule called TSLP that sits upstream of multiple inflammatory pathways.15PubMed Central. Biologic Therapies for Severe Asthma: Current Insights and Future Directions
The evidence on these biologics is encouraging. They reduce flare-ups and hospital admissions, decrease reliance on oral corticosteroids, and improve lung function and quality of life in people with severe asthma driven by a specific type of immune response (type 2 inflammation).16PubMed. Biologic therapies for severe asthma with type 2 inflammation: current evidence, patient selection, and future perspectives Selecting the right biologic hinges on blood markers: eosinophil counts, IgE levels, and exhaled nitric oxide help predict which drug will work best for a given patient.17PubMed Central. Biologic therapies for severe asthma with persistent type 2 inflammation These drugs are expensive, typically require injections every few weeks, and are currently reserved for patients with documented severe disease that does not respond to standard therapy.
Mechanical Ventilation in Acute Lung Injury
When pulmonary inflammation becomes severe enough to cause ARDS, mechanical ventilation is often lifesaving, but how the ventilator is set matters enormously. A landmark trial found that using smaller breath volumes (around 6 mL per kilogram of predicted body weight) reduced death rates compared to larger volumes (around 12 mL per kilogram): roughly 31% mortality versus 40%.18PubMed. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome The logic is that inflamed lungs have many collapsed or fluid-filled regions, so forcing large volumes of air into the remaining functional areas overstretches them and worsens the injury.
A later systematic review pooling data from multiple trials confirmed the benefit, finding roughly a 21% relative reduction in the risk of death at 28 days with lower tidal volumes.19Scientific Reports. Usefulness of low tidal volume ventilation strategy for patients with acute respiratory distress syndrome: a systematic review and meta-analysis Low tidal volume ventilation is now standard of care in ARDS. Additional strategies like prone positioning (lying face-down to redistribute airflow) and careful fluid management further reduce the harm that mechanical ventilation can inflict on already-damaged lungs.
From Inflammation to Fibrosis
One of the most important things to understand about pulmonary inflammation is that it does not always resolve cleanly. When inflammation persists or is severe, the repair process can go awry. Instead of restoring normal tissue, the lungs lay down excessive scar tissue, a process known as fibrosis. An imbalance in signaling molecules, particularly an overproduction of certain growth factors, can convert what should be a controlled healing response into pathological scarring.20PubMed Central. Pulmonary fibrosis: pathogenesis, etiology and regulation
The cells responsible are myofibroblasts, which cluster at sites of active scarring and deposit structural proteins that stiffen the tissue and destroy the delicate architecture of the air sacs.21European Respiratory Journal. The pathogenesis of pulmonary fibrosis: a moving target In ARDS, this timeline has been mapped through autopsy studies: during the first week after onset, the damage is mostly fluid and inflammatory cells, with fibrosis rarely present. Beyond three weeks, proliferative changes appear in all patients, and fibrosis is evident in about two-thirds.22PubMed. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies That first-week window is what makes early and aggressive anti-inflammatory treatment so critical: once fibrosis sets in, the damage becomes much harder to reverse.
When Lung Inflammation Affects the Rest of the Body
Pulmonary inflammation does not always stay in the lungs. In people with COPD, frequent exacerbations push inflammatory molecules from the lungs into the bloodstream, where they can promote vascular damage and increase the risk of heart attack. Elevated levels of TNF-α, IL-6, and C-reactive protein originating from inflamed lung tissue contribute to dysfunction of blood vessel walls, a step that accelerates the buildup of arterial plaques.23PubMed Central. Inflammation as the nexus: exploring the link between acute myocardial infarction and chronic obstructive pulmonary disease This “systemic spillover” is one reason why COPD is associated with a substantially increased cardiovascular risk, not just breathing problems.
Severe acute lung injury, as in ARDS, can similarly trigger multi-organ dysfunction. The same inflammatory mediators that damage the lung barrier can circulate throughout the body and injure the kidneys, liver, and other organs. This is why patients hospitalized with severe ARDS often require monitoring and support for organ systems far beyond the lungs.
The Gut-Lung Axis
An area of growing research interest is the connection between the gut microbiome and lung inflammation. The community of bacteria living in the intestines produces metabolites, especially short-chain fatty acids like acetate, propionate, and butyrate, from the fermentation of dietary fiber. These molecules travel through the bloodstream to the lungs, where evidence suggests they can dampen inflammatory responses and support immune balance.24Dietary Supplements and Nutraceuticals. Short-chain fatty acids and the gut–lung axis: implications for pulmonary inflammation Other gut-derived metabolites, including certain tryptophan byproducts and secondary bile acids, appear to have similar anti-inflammatory effects when they reach the lungs.25PubMed Central. The Gut-Lung Microbiome Crosstalk and Pulmonary Disease
The gut-lung axis works both ways: disruptions in the gut microbiome (from antibiotics, poor diet, or illness) can alter immune responses in the lungs, and respiratory diseases can shift the composition of gut bacteria.26PubMed Central. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks This does not yet translate into specific clinical recommendations; no one can prescribe a probiotic cocktail to treat asthma. But it adds context to the observation that a fiber-rich diet and a healthy gut may indirectly support lung health.
Resolvins and the Biology of Resolution
The body has its own built-in brake system for inflammation. A family of molecules called resolvins, derived from omega-3 fatty acids, actively signals immune cells to stand down once the threat has passed. They prevent unchecked neutrophil swarming, reduce the production of inflammatory signaling molecules and reactive oxygen species, and promote the cleanup of dead cells from inflamed tissue.27PubMed Central. Resolvins: natural agonists for resolution of pulmonary inflammation When this resolution program fails or is overwhelmed, inflammation persists and tissue damage accumulates. Researchers are exploring whether synthetic versions of resolvins could be used therapeutically to help inflamed lungs return to a normal state faster, though this work is still largely preclinical.
Post-Viral Inflammation That Lingers
One pattern that has received increased attention is inflammation that persists long after a respiratory virus has been cleared. In animal studies of respiratory syncytial virus (RSV), researchers found that 30 days after infection, no active virus could be detected in the airways by any method, yet the airways remained abnormally susceptible to inflammation triggered by sensory nerve activation. The content of inflammatory nerve signaling molecules was significantly elevated compared to uninfected controls.28PubMed. Persistent airway inflammation after resolution of respiratory syncytial virus infection in rats This suggests that some viruses leave behind changes in the neural and immune architecture of the lungs that perpetuate inflammation even after the infection itself is over.
Disruption of the lung’s resident microbial communities may also play a role. Viral infections alter the composition of bacteria living in the respiratory tract, and these altered communities can sustain inflammation, damage the lung lining, and contribute to the development of chronic lung disease.29PubMed Central. Post-viral lung diseases: the microbiota as a key player The clinical relevance is obvious in the post-COVID era, where millions of people experience persistent respiratory symptoms months after clearing the virus, but the phenomenon predates COVID-19 and applies to influenza, RSV, and other respiratory pathogens as well.
Aging and the Vulnerable Lung
As people age, the lungs become increasingly susceptible to inflammation through a process sometimes called “inflammageing.” The aging immune system settles into a baseline state of low-grade chronic inflammation, and the lung’s capacity to handle new challenges, whether infections, pollutants, or autoimmune flares, diminishes.30PubMed. Inflammation, ageing and diseases of the lung: Potential therapeutic strategies from shared biological pathways This is why older adults are disproportionately affected by pneumonia, ARDS, COPD exacerbations, and pulmonary fibrosis. The same insult that a younger person’s lungs might resolve in days can spiral into prolonged inflammation, tissue destruction, and impaired recovery in an older adult. Recognizing this vulnerability shapes clinical decisions about vaccination, early treatment of respiratory infections, and aggressive management of environmental exposures in aging populations.